Trials / Completed
CompletedNCT01523860
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
Brief Induction Chemoimmunotherapy With Rituximab + Bendamustine + Mitoxantrone Followed by Rituximab in Elderly Patients With Advanced Stage Previously Untreated Follicular Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Fondazione Italiana Linfomi - ETS · Academic / Other
- Sex
- All
- Age
- 65 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a brief chemoimmunotherapy with the combination of Rituximab + Bendamustine + Mitoxantrone in elderly patients with advanced stage Follicular Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab, Mitoxantrone, Bendamustine | Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2012-02-01
- Last updated
- 2016-03-01
Locations
37 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01523860. Inclusion in this directory is not an endorsement.